Paraplatin
(Carboplatin)ApprovedSmall molecule
Carboplatin is a chemotherapy drug used to treat various cancers, including ovarian cancer, lung cancer, and others. It works by damaging cancer cell DNA to stop them from growing and dividing.[2] Paraplatin is currently approved and in use across 252 indications[4].[1]
Paraplatin is one of 1735 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Approved.
252
Indications
2,371
Total Trials
32
Active Trials
1,734
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 251 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Approved
Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer28 trials
Show 25 more trials
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
Unknown status·PPeople's Hospital of Guangxi Zhuang Autonomous Region·Phase 2·NCT02407366·80 enrolled
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00083083·250 enrolled
Breast Cancer24 trials
Show 21 more trials
Small Cell Lung Cancer12 trials
Show 9 more trials
Neuroblastoma10 trials
Show 7 more trials
Ovarian Cancer9 trials
Show 6 more trials
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00006356·38 enrolled
82 more indications
Lung Cancer6 trials
Carboplatin4 trials
Primary Peritoneal Cancer3 trials
Patients With Advanced Solid Tumors3 trials
Triple-Negative Breast Cancer3 trials
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
Not yet recruiting·—·Phase 2·NCT06407310·25 enrolled
Endometrial Cancer3 trials
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06413992·117 enrolled
Germ Cell Tumor3 trials
Cervical Cancer3 trials
Fallopian Tube Cancer3 trials
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT03462212·290 enrolled
Esophageal Adenocarcinoma2 trials
Pembrolizumab2 trials
Genetic Predictors of Benefit to Pembrolizumab
Terminated·—·Phase 2·NCT02710396·19 enrolled
Chemotherapy2 trials
Peritoneal Cancer2 trials
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Active, not recruiting·—·Phase 1·NCT01970722·40 enrolled
Prostate Cancer2 trials
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Completed·—·Phase 2·NCT00134706·30 enrolled
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Recruiting·—·Phase 1·NCT06303713·37 enrolled
Head and Neck Cancer2 trials
Lung Adenocarcinoma2 trials
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
Active, not recruiting·—·Phase 4·NCT05689671·136 enrolled
Primitive Neuroectodermal Tumor2 trials
Lymphoma2 trials
Esophageal Cancer2 trials
Efficacy2 trials
Bone Marrow Transplantation2 trials
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled
Cholangiocarcinoma2 trials
Pancreatic Cancer1 trial
Stage III Primary Peritoneal Cancer1 trial
Malignant Solid Tumors1 trial
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Terminated·—·Phase 1/2·NCT00788125·7 enrolled
Ependymoma1 trial
Tyrosine Kinase Inhibitors1 trial
Squamous Cell Lung Carcinoma1 trial
Head and Neck Squamous Cell Cancer1 trial
Relapsed/Refractory AML1 trial
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS
Completed·—·Phase 2·NCT00053287·42 enrolled
Mucosal Melanoma1 trial
Urinary Tract Cancer1 trial
Nausea and vomiting1 trial
Recurrent Head and Neck Cancer1 trial
Cancer of the Head and Neck1 trial
Central Nervous System1 trial
Safety and Efficacy1 trial
Epstein Barr Virus1 trial
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
Completed·—·Phase 2·NCT00953420·20 enrolled
Adenocarcinoma1 trial
Ovarian Carcinoma1 trial
Malignant Glioma1 trial
Head and Neck Cancers1 trial
Laryngeal Cancer1 trial
Solid Tumours1 trial
Vulvar Cancer1 trial
Chronic Myelogenous Leukemia1 trial
Central Nervous System Cancer1 trial
Adjuvant Therapy1 trial
Nasopharyngeal Carcinoma1 trial
Neoadjuvant Treatment1 trial
Oropharynx Cancer1 trial
Phase II1 trial
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05870319·376 enrolled
Neoadjuvant Immunotherapy1 trial
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04943029·30 enrolled
Locally Advanced Cancer1 trial
Relapsed or Refractory1 trial
Metastatic Melanoma1 trial
Primary Peritoneal1 trial
Spinal Cord Tumor1 trial
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
Completed·—·Phase 2·NCT00541138·50 enrolled
Solid Tumors1 trial
Advanced NSCLC1 trial
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT03987867·30 enrolled
Small Cell Lung Carcinoma1 trial
ALK-positive Advanced NSCLC1 trial
Glioma1 trial
Melanoma1 trial
Clear Cell Carcinoma1 trial
Metastatic Solid Tumors1 trial
Locally Advanced Head and Neck Cancer1 trial
Liposomal Doxorubicin1 trial
Recurrent or Refractory Solid Tumors1 trial
Locally Advanced1 trial
Stage IV Ovarian Epithelial Cancer1 trial
Solid Tumor Malignancies1 trial
Regulatory
FDA Approval Timeline[5]
Mar 3, 1989
PARAPLATIN
NDA NDA019880
Jul 14, 2003
PARAPLATIN
NDA NDA020452
Aug 8, 2025
KYXATA
NDA NDA219921
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Paraplatin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]